SIGLEC5 Antikörper (C-Term)

Produktnummer ABIN5534705

Produktdetails anti-SIGLEC5 Antikörper

Target: SIGLEC5 (Sialic Acid Binding Ig-Like Lectin 5 (SIGLEC5))

Bindungsspezifität: AA 482-513, C-Term

Reaktivität: Human, Maus

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser SIGLEC5 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB)

Aufreinigung: This antibody is purified through a protein A column, followed by peptide affinity purification.

Immunogen: This SIGLEC5 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 482-513 amino acids from the C-terminal region of human SIGLEC5.

Isotyp: Ig Fraction

Anwendungsinformationen

Applikationshinweise: For WB starting dilution is: 1:1000

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 0.5 mg/mL

Buffer: Supplied in PBS with 0.09 % (W/V) sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Details zu SIGLEC5

Target: SIGLEC5 (Sialic Acid Binding Ig-Like Lectin 5 (SIGLEC5))

Andere Bezeichnung: SIGLEC5 (SIGLEC5 Produkte)

Synonyme: CD170 antikoerper, CD33L2 antikoerper, OB-BP2 antikoerper, OBBP2 antikoerper, SIGLEC-5 antikoerper, sialic acid binding Ig like lectin 5 antikoerper, sialic acid-binding Ig-like lectin 5 antikoerper, sialic acid binding Ig-like lectin 5 antikoerper, SIGLEC5 antikoerper, LOC100597560 antikoerper, Siglec5 antikoerper

Hintergrund: SIGLECs are members of the immunoglobulin superfamily that are expressed on the cell surface. Most SIGLECs have one or more cytoplasmic immune receptor tyrosine-based inhibitory motifs (ITIM). SIGLECs are typically expressed on cells of the innate immune system, with the exception of the B-cell expressed SIGLEC6. Sequence analysis predicted that the 697-amino acid SIGLEC10 protein contains a signal peptide, an N-terminal V-set Ig-like domain and four C2-set Ig-like domains, five potential N-linked glycosylation sites, a transmembrane region, and a 126-residue cytoplasmic tail with 3 putative ITIMs. Northern blot analysis detected a major 3.0-kb SIGLEC10 transcript, with highest levels in spleen, lymph node, blood leukocytes, and appendix. Little or no expression was observed in pancreas, thyroid, and testis. Flow cytometric analysis demonstrated eosinophil-specific expression of SIGLEC10, but at a lower level than that of SIGLEC8. Expression was also detected on monocytes and a CD16-positive/CD56-negative natural killer-like lymphocyte population. After sialidase treatment, which is necessary for unmasking the sialic acid-binding site on SIGLECs interacting with cell surface sialic acids, cells expressing SIGLEC10 bound to red blood cells. Immunoprecipitation analysis indicated expression of a 100- to 120-kD monomeric protein, higher than the predicted molecular mass, suggesting that SIGLEC10 is glycosylated.

Molekulargewicht: 61 kDa

Gen-ID: 8778

UniProt: O15389